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Running title: Menstrual pain and ovarian cancer risk 
 
Novelty and impact: In this large international pooled analysis of case-control studies, we 
observed a small increase in risk of ovarian cancer for women reporting severe menstrual pain. 
Given the high prevalence of menstrual pain, this association should be further examined in 
prospective studies. 
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Abstract  
Menstrual pain, a common gynecological condition, has been associated with increased risk of 
ovarian can er in some, but not all studies. Furthermore, potential variations in the association 
between menstrual pain and ovarian cancer by histologic subtype have not been adequately 
evaluated due to lack of power. We assessed menstrual pain using either direct questions about 
having experienced menstrual pain, or indirect questions about menstrual pain as indication for 
use of hormones or medications. We used multivariate logistic regression to calculate the odds 
ratio (OR) for the association between severe menstrual pain and ovarian cancer, adjusting for 
potential confounders, and multinomial logistic regression to calculate odds ratios for specific 
histologic subtypes. We observed no association between ovarian cancer and menstrual pain 
assessed by indirect questions. Among studies using direct question, severe pain was associated 
with a small but significant increase in overall risk of ovarian cancer (OR=1.07, 95% CI: 1.01-
1.13), after adjusting for endometriosis and other potential confounders. The association 
appeared to be more relevant for clear cell (OR=1.48, 95% CI: 1.10-1.99) and serous borderline 
(OR=1.31, 95% CI: 1.05-1.63) subtypes. In this large international pooled analysis of case-control 
studies, we observed a small increase in risk of ovarian cancer for women reporting severe 
menstrual pain. While we observed an increased ovarian cancer risk with severe menstrual 
pain, the possibility of recall bias and undiagnosed endometriosis cannot be excluded. Future 
validation in prospective studies with detailed information on endometriosis is needed.  
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INTRODUCTION 
With more than 14,000 estimated deaths in 2017, ovarian cancer is the fifth leading cause of 
female cancer deaths in the U.S., and the most lethal gynecologic malignancy (1). Less than 15% 
of ovarian cancers are diagnosed at an early stage before cancer has spread outside of the 
ovary. Overall prognosis is poor with a 5-year survival of 45% (1).  Understanding novel ovarian 
cancer risk factors could help identify women at higher risk of disease who might benefit from 
screening.   
Inflammation has been hypothesized to play an important role in ovarian carcinogenesis (2). 
Inflammatory conditions including endometriosis (3) and pelvic inflammatory disease (4) have 
been associated with an increased risk of ovarian cancer, while tubal ligation, which may reduce 
exposure to proinflammatory factors, (5) and regular use of non-steroidal anti-inflammatory 
drugs (NSAID) (6) have been associated with a reduction in risk.   
Menstrual pain, also known as dysmenorrhea is a common gynecological condition associated 
with increased inflammation (7) and has previously been evaluated in relation to ovarian cancer 
risk (8-14). However, the majority of the studies were small and inadequately adjusted for 
potential confounders.  Furthermore, due to relatively small numbers of participants, previous 
studies were not adequately powered to evaluate whether this association might differ by 
histological subtype, which is important for understanding the potential mechanism underlying 
any observed association.  
We examined the association between severe menstrual pain and ovarian cancer risk among 
10,592 cases and 13,320 controls participating in the Ovarian Cancer Association Consortium, 
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an international collaboration dedicated to studying factors affecting ovarian cancer risk and 
survival.  
MATERIALS AND METHODS 
Study population 
The Ovarian Cancer Association Consortium (OCAC) was founded in 2005 to foster 
collaborations in discovering and validating genetic variants associated with ovarian cancer risk 
(3,15). The analyses presented here are restricted to nine studies with available information on 
menstrual pain: Australian Ovarian Cancer Study (AUS) (11), the Connecticut Ovarian Cancer 
Study (CON) (16), Diseases of the Ovary and their Evaluation (DOV) (17,18) , Hawaii Ovarian 
Cancer Study (HAW) (19,20), Hormones and Ovarian Cancer Prediction Study (HOP) (21), 
Malignant Ovarian Cancer Study (MAL) (22), New England Case Control Study (NEC) (23), North 
Carolina Ovarian Cancer Study (NCO) (24,25), and Los Angeles County Case-Control Studies of 
Ovarian Cancer (USC) (26). Characteristics of the studies are shown in Supplementary Table 1. 
In total, our analysis included data from seven case-control studies conducted in the United 
States (CON, DOV, HAW, HOP, NCO, NEC, USC), one study conducted in Australia (AUS), and 
one study conducted in Denmark (MAL).  
We excluded women with non-epithelial tumors or tumors of unknown origin (n=78) and 
women with no available information on menstrual pain (n=605), resulting in a final analytic 
dataset of 10,592 cases and 13,320 controls. There were 8,275 invasive and 2,062 borderline 
cases, as well as 255 cases of unknown morphology (Table 1). Invasive epithelial tumors were 
further categorized by histologic subtype: high-grade serous (n=3,255), low-grade serous 
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(n=1,199), mucinous (n=521), endometrioid (n=1,251), clear cell (n=639), and other (n=953). 
Borderline tumors were characterized as serous (n=1,165), mucinous (n=801) or other (n=67). 
All studies included in this analysis had obtained written informed consents from all study 
participants, and had approval from the relevant ethics committees.  
Study variables 
Questions relating to severe menstrual pain differed between sites included in this analysis 
(summarized in Table 2). In AUS, CON, NCO and NEC the questionnaire asked whether the 
participant experienced severe or significant menstrual pain. These questions will be referred to 
here as direct. Five studies (DOV, HAW, HOP, MAL and USC) asked about menstrual pain as an 
indication for using various over the counter or prescription medications, including NSAIDs, oral 
contraceptives, hormones or intrauterine devices (IUD). These questions will be referred to 
here as indirect. Menstrual pain requiring use of any of those medications was considered 
severe.  In NCO, participants were asked if they experienced severe cramping during periods in 
the two years prior to diagnosis (cases), or in the last two years (controls). Since these 
questions only pertained to women who were menstruating within the last two years, the 
analysis of NCO was restricted to premenopausal women.   
Participants of AUS and NCO who reported severe pain were further asked to provide 
additional details about menstrual pain, such as frequency of pain (AUS, NCO), age at onset of 
pain (AUS, NCO), total number of years with pain (AUS, NCO), whether they had seen a doctor 
about the pain (AUS, NCO), or taken a medication for the pain (NCO). For AUS and NCO, we 
created a variable combining information about menstrual pain severity and frequency, with 
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the following values: no pain or pain not severe, severe pain occurring sometimes or rarely, 
severe pain occurring often.  
The following variables were obtained as part of the core dataset and were harmonized by 
OCAC study sites: age (continuous), race (white, other), duration of use of oral contraceptives 
(OC; continuous), parity (0, 1, 2, 3, 4 or more pregnancies), family history of breast or ovarian 
cancer in a first-degree relative (yes, no), tubal ligation (yes, no), self-reported endometriosis 
(yes, no), body mass index (BMI, continuous) 1 year before diagnosis (cases) or interview 
(controls), BMI (continuous) at the age 18, age at menarche (continuous), genital powder use 
(nonuser, genital use, non-genital use, unknown), regular (at least once per week) use of 
aspirin, regular (at least once per week) use of other NSAIDs, menopausal status 
(peri/premenopausal, postmenopausal, unknown), and smoking status (never, former, current, 
unknown).  
Information on the following variables was obtained from individual studies, and harmonized 
for this analysis: history of pelvic inflammatory disease, polycystic ovary syndrome, fibroids, 
ovarian cysts and irregular periods (all coded as yes, no, unknown). 
Statistical analysis 
Study-specific odds ratios (ORs) and 95% confidence intervals (95% CI) for the association 
between severe menstrual pain and risk of ovarian cancer were estimated using unconditional 
logistic regression. In the minimally adjusted model, we adjusted for race and age. In the fully 
adjusted model we additionally adjusted for a priori selected ovarian cancer risk factors 
including parity, OC use, family history of breast or ovarian cancer, tubal ligation, and 
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endometriosis (3,5,27-29), even though none of the factors changed the observed association 
by more than 10%. We also considered potential confounding by BMI, age at menarche, genital 
powder use, history of pelvic inflammatory disease, ovarian cysts, polycystic ovary disease, 
irregular periods, fibroids, menopausal status and smoking; however, none of those factors 
altered the effect estimates by more than 10% and they were therefore not included in the final 
models. To evaluate heterogeneity between studies we pooled the study-specific estimates 
using random-effects meta-analysis. Heterogeneity between studies was evaluated using I
2
. 
Multinomial logistic regression was used to estimate the association between menstrual pain 
and risk of ovarian cancer by behavior (borderline vs. invasive) and histologic subtype. 
Likelihood ratio tests were performed to test the association differs significantly by behavior 
and histologic subtype.  
We perform d stratified analyses to evaluate effect modification by age (< 50 or ≥ 50 years, 
study population median), menopausal status (premenopausal, postmenopausal), BMI 1 year 
before diagnosis or interview (<25 kg/m
2
, ≥25 kg/m
2
), median BMI at age 18 (<20.8 kg/m
2
, 
≥20.8 kg/m
2
), endometriosis (yes, no, unknown), regular aspirin use (yes, no), regular NSAID use 
(yes, no), parity (nulliparous, parous), and OC use (<1 year, ≥ 1 year). The stratified analyses 
were performed using a pooled dataset of all studies, adjusting for study site in addition to 
other variables described above. To test for significance of any effect modification, we created 
a cross product between menstrual pain and each stratifying variable and performed likelihood 
ratio tests to compare models with or without interaction terms. We performed a sensitivity 
analysis to evaluate the influence of exposure misclassification using a method previously 
described (30).  Briefly, we evaluated how different degrees of misclassification of menstrual 
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pain might influence the associations.  Specifically, we were interested in what degree of 
misclassification would lead to the observed effect estimate if the true effect estimate was 
1.00. Furthermore, we also performed a sensitivity analysis excluding NCO participants since 
the question about menstrual pain in this study was referring to a recent period (Table 2) and 
therefore more prone to reverse causation. 
All analyses were performed using SAS v9.3 (SAS Institute, Cary, NC), except for meta-analysis 
and multinomial logistic regression, which were performed using Stata IC/12 (StataCorp, 
College Station, TX). All p values were two-sided, and a significance level of 0.05 was used.  
 
RESULTS 
Characteristics of ovarian cancer cases and controls are shown in Table 1. Compared to 
controls, cases were more likely to be nulliparous, less likely to have had a history of tubal 
ligation, and had a shorter duration of OC use. In addition, ovarian cysts, fibroids, family history 
of breast or ovarian cancer, use of genital powder, and severe menstrual pain were more 
frequent in cases than in controls.   
The prevalence of severe menstrual pain in controls varied widely across the different sites 
included in this analysis (2.7% to 55.6%; Table 2), as expected given the heterogeneity of the 
questions pertaining to menstrual pain.  Overall, severe menstrual pain was less common 
among sites that asked an indirect question (2.7% to 10.0%, average prevalence = 5.3%) 
compared to those that asked direct questions (9.5% to 55.6%, average prevalence = 30.3%).  
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The highest prevalence was reported for AUS (55.6%), where participants were asked about 
ever having experienced very painful period pain, followed by NCO (43.2%) where participants 
were asked about severe menstrual cramping for duration of least 1 year in the 2 years 
preceding diagnosis, and CON (34.9%) that asked about typically experiencing significant pain.  
Report of severe menstrual pain was lowest in the USC study (2.7%) which asked whether 
painful periods were an indication for taking birth control pills or hormones.  
Figure 1A shows the association between several menstrual pain and ovarian cancer risk for the 
four studies that asked direct questions about menstrual pain. Severe pain was associated with 
a small but statistically significant increase in risk for women who reported severe menstrual 
pain, compared to women without severe menstrual pain (OR = 1.07, 95% CI: 1.01-1.13). For 
studies that used indirect questions, there was no association between severe menstrual pain 
and ovarian cancer risk (OR = 0.98, 95% CI: 0.89-1.07) (Figure 1B). There was no heterogeneity 
between study sites with either direct (P-heterogeneity=0.74) or indirect questions about 
menstrual pain (P-heterogeneity=0.27).  
Since indirect questions likely failed to identify women with severe pain (as only those who 
reported pain as a reason for medication use would have been identified by these questions), 
we restricted the following analyses to the four studies that asked direct questions (AUS, CON, 
NCO, NEC).  In the pooled analysis, we evaluated the association between ovarian cancer risk 
and the combined variable for severe menstrual pain presence and frequency (AUS, NCO). 
Compared to women with no severe pain, those with rare severe pain were not at a 
significantly higher risk (OR: 0.99, 95% CI: 0.83-1.17), while those with frequent severe pain 
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were at a 17% increased risk of ovarian cancer (OR: 1.17, 95% CI: 1.00-1.38) (Table 3). 
Compared to women with no severe pain, those with duration of severe pain of less than 12 
years (median duration of pain among women with severe pain) were not at increased risk of 
ovarian cancer (OR=0.95, 95% CI: 0.80-1.12), while those with duration longer than 12 years 
had a 18% increase in risk of ovarian cancer (OR=1.18, 95% CI: 0.99-1.40) (Table 3). Age at 
menstrual pain onset (AUS, NCO) was not associated with risk of ovarian cancer (Table 3).  
In stratified pooled analyses (Supplementary Table 2), we observed no statistically significant 
effect modification by age, menopausal status, regular aspirin use, regular NSAID use, parity, 
OC use, endometriosis, and tubal ligation (P-interaction ≥ 0.15). Although not significant, 
differences in the association by BMI 1 year before diagnosis or interview were suggestive (P-
interaction = 0.06).  The association was not significant among women with BMI < 25 kg/m
2
 
(OR=1.01, 95% CI: 0.87-1.23), while there was a 21% increase in risk among women with BMI > 
25 kg/m
2
 (OR:  1.21, 95% CI: 1.04-1.41).   
Severe menstrual pain was more frequent among women with endometriosis (51%), compared 
to those without endometriosis (30%). There was no difference in the association between 
menstrual pain and ovarian cancer risk with (OR=1.07, 95% CI: 1.01-1.13) or without (OR=1.08, 
95% CI: 1.02-1.14) adjusting for endometriosis.  
Since severe pain might lead to OC use, and OC use could therefore lie on a causal pathway 
between severe pain and ovarian cancer, adjusting for OC use could bias the association toward 
null. We therefore evaluated the association between menstrual pain and overall risk of ovarian 
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cancer in a multivariate model with no adjustment for OC use, and observed no change in 
association (OR=1.06, 95% CI: 1.01-1.12).  
In analyses by histological subtypes (Figure 2 A-E), we observed a statistically significant 
association between severe menstrual pain and clear cell ovarian cancer (OR=1.48, 95% CI: 
1.10-1.99), and a suggestion of association for endometrioid (OR=1.24, 95% CI: 0.99-1.54) and 
high-grade serous cancers (OR=1.13, 95% CI: 0.97-1.31). We observed no association for low-
grade serous (OR=1.12, 95% CI: 0.90-1.39), or mucinous subtypes (OR=1.18, 95% CI: 0.63-2.19) 
although these analyses were limited by small numbers.  However, the overall likelihood test 
has shown no significant difference in association by histological subtype (P-
heterogeneity=0.53).  Severe menstrual pain was associated with increased risk of the serous 
borderline (OR=1.31, 95% CI: 1.05-1.83), but not mucinous borderline subtype (OR=1.00, 95% 
CI: 0.77-1.29; Figure 3 A-B), although there was no overall significant difference in association 
among those two subtypes (P-heterogeneity=0.61). There was no significant heterogeneity for 
associations by histological subtypes across study sites, except for the mucinous invasive 
subtype (n=169) (P-heterogeneity=0.05). Since the association between menstrual pain and 
clear cell tumors was previously reported for NEC study, we performed a sensitivity analysis 
excluding NEC participants, and observed a suggestive association between menstrual pain and 
clear cell ovarian cancer (OR=1.40, 95% CI: 0.96-2.40). We performed a sensitivity analysis of 
sites with direct questions after excluding NCO, since this site asked about menstrual pain in a 
period shortly before diagnosis, and therefore had a higher potential for recall bias or reverse 
causation. Excluding NCO did not significantly change the association between severe 
menstrual pain and overall ovarian cancer (OR: 1.13, 95% CI: 1.01-1.27).  
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To evaluate the impact of potential over-reporting of menstrual pain on the overall effect 
estimate, we performed an analysis where specificity of menstrual pain reporting in cases 
varied but in controls was set to 0.99. We observed that a specificity of 0.94 among cases would 
be required to inflate the effect estimate to the observed OR = 1.07. We also examined 
whether the prevalence of pain severe enough to seek medical treatment differed between 
cases and controls who reported severe menstrual pain.  This more objective measure of 
menstrual pain was assessed in the AUS and NCO studies.  Among women who reported 
experiencing severe pain, 43% of cases (n=1,011) and 42% of controls (n=954) had consulted a 
physician suggesting that cases were not simply over-reporting less severe pain compared to 
controls.   
DISCUSSION 
In this large pooled analysis of case control studies, we observed a suggestive increase in 
ovarian cancer risk for women who reported severe menstrual pain, compared to those without 
such pain. Furthermore, we observed that the association was restricted to women who 
experienced menstrual pain more frequently or for a longer duration (>12 years). The risk 
associated with severe menstrual pain appeared to be most relevant for clear cell and 
borderline serous subtypes.  
The association between menstrual pain and risk of ovarian cancer was evaluated using two 
distinct types of question. While certain sites asked whether the participant experienced severe 
or significant menstrual pain (direct question), the others asked about menstrual pain as an 
indication for using various medications (indirect question). While there is likely a comparable 
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specificity between two question types, the indirect question is likely to be less sensitive to 
detect women with severe menstrual pain since it would fail to identify women with severe 
pain that did not use any of the listed medications. The type of question used to assess severe 
menstrual pain varied widely between studies. As expected, the prevalence of severe menstrual 
pain varied between the study sites, which was likely related to the difference in the questions 
asked, but could also be due to difference in perception of pain across cultures. While we 
initially considered sites with both direct and indirect questions, the added potential for 
misclassification given the indirect nature of the question, which required a woman to indicate 
pain as a reason for taking analgesics or hormones, led us to restrict our remaining analyses to 
the studies that asked directly about severe menstrual pain. We cannot rule the possibility that 
women with most severe pain would have been identified using indirect question and that 
stronger association would be expected among these women. However, since the prevalence of 
severe menstrual pain in studies with indirect question was low (2.7% to 10%) we would likely 
not have power to detect a significant association. Furthermore, since this question is less 
sensitive, and would fail to identify all the women with severe menstrual pain, this would lead 
to exposure misclassification and bias the association toward the null.  
Two studies included in this analysis had previously evaluated the association between 
menstrual pain and ovarian cancer using direct question (8,11) and had shown differing results. 
One  reported a significant increase in ovarian cancer risk (8), while the other reported no 
significant association (11). Four additional studies reported no significant association; 
however, it is not clear what type of question was used to assess history of menstrual pain in 
those studies.  Therefore, we are not able to directly compare our results (9,10,13,14).  
Page 17 of 31
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
17 
 
The large number of cases in the analysis allowed us to evaluate the association between 
menstrual pain and individual histologic subtypes. We observed an increased risk for clear cell 
and serous borderline tumors, however there was no statistically significant difference in the 
association neither among invasive, nor among borderline subtypes. Increased risk of clear cell 
subtype had been previously reported by NEC study, which is included in this analysis, and 
results remained borderline significant after excluding NEC participants. However, one cannot 
exclude the possibility that observed significant association is due to chance or multiple 
comparisons.  
Menstrual pain (dysmenorrhea) can be either primary or secondary. While secondary 
dysmenorrhea is caused by endometriosis, fibroids, adenomyosis, or pelvic inflammatory 
disease (31), primary dysmenorrhea is thought to be caused by inflammatory processes. We 
observed no significant change in effect estimate after adjusting for endometriosis, fibroids, 
and pelvic inflammatory disease, suggesting that the observed association is not due to 
secondary dysmenorrhea as a result of these conditions. Primary dysmenorrhea is thought to 
be a consequence of increased prostaglandin synthesis shortly before menstruation onset, 
which increases uterine contractility (7,32). Women with severe menstrual pain have higher 
levels of prostaglandins (33-35) as well as other inflammatory molecules such as leukotrienes 
(36,37) and platelet activating factors (36)  in menstrual blood. Through the process of 
retrograde menstruation, which occurs in up to 90% of women with intact fallopian tubes (38-
40), those inflammatory factors could reach the tubal epithelium as well as ovarian tissue, and 
promote carcinogenesis at those sites. Our results support such a hypothesis, since severe 
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menstrual pain was not associated with ovarian cancer in women with a history of tubal 
ligation.  
The association between menstrual pain and ovarian cancer was similar among aspirin or NSAID 
users, and non-users. If the mechanism underlying the association between menstrual pain and 
ovarian cancer is inflammation, one would expect the association to be attenuated among 
aspirin or NSAID users. However, our question on regular medication use did not assess dose of 
intake but only distinguished between non-weekly versus one or more times of use per week. 
Furthermore, it is unknown whether the use of aspirin and NSAIDs coincided with occurrence of 
menstrual pain.  
Endometriosis is a common gynecological condition associated with significant menstrual pain 
(41), and an established ovarian cancer risk factor (3). In our study adjusting for endometriosis 
did not alter the association between severe menstrual pain and ovarian cancer risk. Since 
endometriosis in our study was self-reported, and final diagnosis of endometriosis requires 
laparoscopy, it is possible that there might be residual confounding by undiagnosed 
endometriosis among our participants. However, if menstrual pain was merely a symptom of 
undiagnosed endometriosis, one would expect a stronger association among women with 
diagnosed endometriosis, which is not the case in this analysis (Supplementary Table 2). Further 
studies where the presence of endometriosis is clinically evaluated are needed to disentangle 
menstrual pain from endometriosis.  
Retrospective studies are susceptible to potential recall bias, where exposure recall may differ 
between cases and controls. For example, cases might be prone to over-report severe 
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menstrual pain, which would lead to an overestimation of the association between pain and 
ovarian cancer risk. We found that a decrease in specificity of accurately reporting severe 
menstrual pain of 6% among cases would nullify the observed effect estimate. To further 
address this potential over-reporting of menstrual pain by cases, we examined a more objective 
indicator, namely menstrual pain that was severe enough to result in consultation with a 
physician. If cases were indeed over reporting pain, one would expect a smaller proportion of 
cases who reported severe menstrual pain to have consulted a physician, compared to controls. 
However, we observed a comparable percentage of cases with severe pain (43%) and control 
subjects (42%) who consulted a physician, suggesting recall bias was not a likely problem in our 
study population. Furthermore, recall bias would be unlikely to lead to differences in the 
association by histologic subtype as there is no reason to suspect that women with 
endometrioid or clear cell tumors would be more likely to over report menstrual pain compared 
to women with high grade serous tumors.  
To our knowledge, this is the largest study and only international collaborative study that has 
evaluated menstrual pain in relation to ovarian cancer. Furthermore, we were able to evaluate 
features of menstrual pain such as age at onset as well as duration and frequency of menstrual 
pain. Due to a large sample size, we were able to examine the association even for the rare 
subtypes of ovarian cancer and identify previously unknown differential associations, in 
particular for borderline cases. We were also able to consider and control for several factors 
associated with underlying causes of menstrual pain.   
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A limitation of this study was the heterogeneity of questions pertaining to severe menstrual 
pain, even among study sites with a direct question. For instance, NCO asked participants about 
severe menstrual pain in the past two years, whereas most studies asked about any history of 
menstrual pain. However, our results remained unchanged after excluding NCO in a sensitivity 
analysis. Since the questions were asked specifically about severe or significant pain, we were 
not able to evaluate the increase in risk for women with milder pain. Our study population was 
predominantly white (87%), and therefore our results might not be generalizable to other 
racial/ethnic groups.   
In summary, our results suggest that severe menstrual pain is associated with a modest, but 
statistically significant, increase in ovarian cancer risk. Furthermore, among women with severe 
menstrual pain ovarian cancer risk increased with higher frequency and longer duration of 
menstrual pain. Since severe menstrual pain is a common condition, even a small increase in 
risk would translate into a substantial impact on a population level. Future studies should 
disentangle the impact of menstrual pain from the one of endometriosis in more detail.  
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Figure Titles and Legends: 
Figure 1.  
Title: 
A. Association between risk of overall ovarian cancer and severe menstrual pain ascertained by 
direct question 
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B. Association between risk of overall ovarian cancer and severe menstrual pain ascertained by 
indirect question 
Legend:  
A. Adjusted for age (continuous, in years), parity (0, 1, 2, 3, 4 or more children), oral contraceptive use 
(<3months, 3 months - < 1 year, 1 - < 5 years, ≥ 5 years), family history of ovarian or breast cancer, tubal 
ligation, race (white, non-white), endometriosis (yes, no, unknown).  
Abbreviations: AUS, Australian Ovarian Cancer Study; CON, Connecticut Ovary Study; NCO, North 
Carolina Ovarian Cancer Study; NEC, New England Case Control Study 
B. Adjusted for age (continuous, in years), parity (0, 1, 2, 3, 4 or more children), oral contraceptive use 
(<3months, 3 months - < 1 year, 1 - < 5 years, ≥ 5 years), family history of ovarian or breast cancer, tubal 
ligation, race (white, non-white), endometriosis (yes, no, unknown).  
Abbreviations: DOV, Diseases of the Ovary and their Evaluation Study; HAW, Hawaii Ovarian Cancer 
Study; HOP, Hormones and Ovarian Cancer Prediction Study; MAL, Malignant Ovarian Cancer Study; 
USC, Los Angeles Count Case-Control Studies of Ovarian Cancer.   
Figure 2.  
Title: Association between severe menstrual pain evaluated using direct question and histological 
subtypes of invasive ovarian cancer 
Legend:  
(A) High-grade serous, (B) Low-grade serous, (C) Mucinous, (D) Clear cell, (E) Endometrioid.  
Abbreviations: AUS, Australian Ovarian Cancer Study; CON, Connecticut Ovary Study; NCO, North 
Carolina Ovarian Cancer Study; NEC, New England Case Control Study 
Figure 3. 
Title: Association between severe menstrual pain evaluated using direct question and histological 
subtypes of borderline ovarian cancer 
Page 22 of 31
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
22 
 
Legend:  
 (A) Serous, (B) Mucinous. Adjusted for age (continuous, in years), parity (0, 1, 2, 3, 4 or more children), 
oral contraceptive use (<3months, 3 months - < 1 year, 1 - < 5 years, ≥ 5 years), family history of ovarian 
or breast cancer, tubal ligation, race (white, non-white), endometriosis (yes, no, unknown).  
Abbreviations: AUS, Australian Ovarian Cancer Study; CON, Connecticut Ovary Study; NCO, North 
Carolina Ovarian Cancer Study; NEC, New England Case Control Study 
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Table 1. Characteristics of ovarian cancer cases and controls 
Characteristics Cases 
(n=10,592) 
Controls 
(n=13,320) 
 Mean (SD) 
Age (years) 55.4 (12.1) 55.3 (12.2) 
Age at menarche (years) 12.8 (7.6) 12.8 (1.6) 
BMI at 1 year before diagnosis or interview 
(kg/m
2
) 
26.9 (6.5) 26.6 (6.2) 
BMI at 18 years (kg/m
2
) 21.5 (3.7) 21.2 (3.4) 
 N (%) 
History of tubal ligation) 1,724 (16) 3,026 (23) 
Parity 
0 
1 
2 
3 
4+ 
 
2,761 (26) 
1,577 (15) 
2,981 (28) 
1,866 (18) 
1,407 (13) 
 
2,068 (16) 
1,814 (14) 
4,442 (33) 
2,865 (22) 
2,131 (16) 
Oral contraceptives use  
<3 months 
3months-1 year 
1-5 years 
>5 years 
 
4,587 (43) 
1,452 (14) 
2,220 (21) 
2,333 (22) 
 
4,478 (34) 
1,548 (12) 
3,021 (23) 
4,273 (32) 
Menopause
a 
Pre/perimenopausal 
Postmenopausal 
 
3,731 (36) 
6,742 (64) 
 
4,920 (37) 
8,196 (62) 
Severe menstrual pain 1,782 (17) 1,815 (14) 
History of endometriosis
a 
978 (9) 870 (7) 
Polycystic ovary syndrome
a 
110 (1) 124 (1) 
History of pelvic inflammatory disease
a 
248 (3) 257 (3) 
History of irregular periods
a 
1,363 (14) 1,791 (15) 
History of ovarian cysts
a 
1,807 (17) 1,842 (14) 
Fibroids
a 
2,130 (21) 2,352 (18) 
Family history of breast or ovarian cancer 1,944 (18) 1,985 (15) 
Race   
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White 
Black 
Asian 
Other/unknown 
9,224 (87) 
301 (3) 
601 (6) 
466 (4) 
11,877 (89) 
317 (2) 
594 (4) 
532 (4) 
Smoking status 
Never 
Current 
Former 
 
4,605 (43) 
1,482 (14) 
2,801 (26) 
 
6,208 (47) 
2,067 (16) 
3,733 (28) 
Regular aspirin use 1,056 (19) 1,785 (19) 
Regular NSAID use 1,307 (23) 2,208 (23) 
Use of genital powder
a 
Non-user 
Genital use 
Non-genital  use 
 
3,297 (50) 
2,030 (31) 
1,176 (18) 
 
4,571 (34) 
2,070 (16) 
1,439 (11) 
Histological subtype
a 
Borderline (n=2,062) 
    Serous 
    Mucinous 
    Other 
   
Invasive (n=8,275)
 
    Serous 
    Mucinous 
    Endometrioid 
   Clear cell 
    Other 
 
 
1165 (56) 
801 (39) 
67 (5) 
 
 
      4,911 (59) 
 521 (6) 
1,251 (15) 
639 (8) 
953 (12) 
 
 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
 
a
Data were missing on menopausal status for 119 cases and 204 controls, endometriosis for 39 cases and 43 controls, on polycystic syndrome for 
1,144 cases and 2,120 controls, on pelvic inflammatory disease for 3,479 cases and 5,459 controls, on history of irregular periods for 1,168 cases 
and 1,397 controls, on history of ovarian cysts for 40 cases and 54 controls, on fibroids for 540 cases and 615 controls, on use of powder for 
4,089 cases and 5,240 controls, on smoking status for 1,704 cases and 1,312 controls, on regular aspirin use for 4,910 cases and 3,665 controls, 
on regular NSAID use on 4,862 cases and 3,665 controls, on cancer invasiveness for 255 cases. 
  
Page 27 of 31
John Wiley & Sons, Inc.
International Journal of Cancer
57
58
59
60
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
27 
 
 
Table 2. Questions relating to menstrual pain by study  
Study 
acronym 
Question relating to severe menstrual pain Type of 
question 
Prevalence 
of severe 
pain in 
controls 
AUS Ever suffered from very painful periods Direct 55.6 % 
CON  Typically had significant pain or discomfort during menstruation in your 20's, 30’s 
or 40’s 
 
Direct 34.9 % 
NEC Severe cramps in 20s and 30s when not pregnant, breastfeeding or using birth control pills Direct 9.5 % 
NCO Severe menstrual cramping during the periods for at least 1 year, in 2 years prior to diagnosis (cases) 
or in the past two years (for controls) 
Painful periods as reason for using birth control, IUD, over the counter or prescription medications 
Direct 43.2 % 
DOVE Cramps or painful ovulation as the main reason you used pill/shot/implant other than for birth 
control 
Severe menstrual cramps as a reason for hormone pill use 
Menstrual pain as indication for taking medication for 5 or more days per month for at least 6 
months 
Indirect 5.5 % 
HAW 
Painful periods as a reason for  birth control pill use 
Painful periods as a reason for use of hormones, aspirin products, aspirin-free products, 
over the counter NSAID, prescription NSAID, prescription pain relievers 
 
Indirect 10.0 % 
HOP Menstrual pain as indication for hormone shot/implant, patch, ring, other hormone medication, 
over the counter aspirin, over the counter inflammation reliever other than aspirin, 
prescription medicine for pain or inflammation 
 
Indirect 7.4 % 
MAL Pain during the period as a reason for taking birth control pills or hormone therapy 
 
Indirect 3.6 % 
USC Painful periods as indication for taking birth control or hormones Indirect 2.7 % 
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Table 3. Association between menstrual pain characteristics and risk of ovarian cancer
a 
in the pooled 
dataset 
 
 Cases/controls OR
b
 (95% CI) 
Menstrual pain frequency   
No pain/pain not severe 803/842 1.00 (ref) 
Severe pain, sometimes/rarely 417/436 0.99 (0.83-1.17) 
Severe pain, often 573/502 1.17 (1.00-1.38) 
Duration of menstrual pain   
No severe menstrual pain 803/842 1.00 (ref) 
Severe pain <12 years  412/485 0.95 (0.80-1.12)   
Severe pain  ≥ 12 years 500/406 1.18 (0.99-1.40) 
P-trend
c
  0.03 
Age at menstrual pain onset
 
  
No severe menstrual pain 803/842 1.00 (ref) 
Pain onset at  <15 years of age
d
 399/372 1.10 (0.92-1.31) 
Pain onset at ≥15 years of age
d
 612/582 1.08 (0.93-1.26) 
P-trend  0.52 
 
a
Restricted to sites with available information on menstrual pain frequency, duration, and age at onset 
(AUS and NCO) 
b
Adjusted for age (years, continuous), site, parity (0, 1, 2, 3, 4 or more children), oral contraceptive use 
(<3months, 3 months - < 1 year, 1 - < 5 years, ≥ 5 years), family history of ovarian or breast cancer, tubal 
ligation, race (white, non-white), and endometriosis (yes, no, unknown).  
c
Years of menstrual pain  
d
Median age at menstrual pain onset 
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Figure 1  
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Figure 2  
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Figure 3  
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